MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T

David A. Place, Patrick J. Faustino, Kirsten K. Berghmans, Peter C Van Zijl, A. Scott Chesnick, Jack S. Cohen

Research output: Contribution to journalArticle

Abstract

Previously we reported that Mn(III)tetra(4-sulfonatophenyl) porphyrin, MnTPPS4, is a contrast agent which can effectively enhance tumor detection by MRI. By imaging 30 additional athymic nude mice bearing subcutaneous MCF-7 WT human breast carcinoma xenografts, we have extended dose-contrast relationships over a wide range of intraperitoneal (IP) doses ranging from 0.025 to 0.50 mmol/kg. The benefits of IP injection are higher possible doses on a volume basis and a reduction in toxicity versus IV administration. Full coronal cross-section images have been obtained on a 2-T spectrometer. Although individual tumor masses displayed different distribution patterns, reflective of their internal morphology, single doses of 0.10 mmol/kg or greater were necessary to produce a detectable effect. At a dose of 0.50 mmol/kg, marked enhancement was produced. Multiple small dosages administered over the course of several days before imaging did not produce increased enhancement. Preliminary results on the new porphyrin derivative, MnTPPS3, indicate that the ratio of the toxic dose to the effective dose may be adjustable to render this class of agents clinically useful.

Original languageEnglish (US)
Pages (from-to)919-928
Number of pages10
JournalMagnetic Resonance Imaging
Volume10
Issue number6
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Porphyrins
Manganese
Heterografts
Nude Mice
porphyrins
Magnetic resonance imaging
mice
manganese
Tumors
Bearings (structural)
tumors
Imaging techniques
dosage
Poisons
Intraperitoneal Injections
Contrast Media
Toxicity
Spectrometers
Neoplasms
Breast Neoplasms

Keywords

  • Contrast agent
  • MnTPPS
  • Porphyrin
  • Tumor

ASJC Scopus subject areas

  • Biophysics
  • Clinical Biochemistry
  • Structural Biology
  • Radiology Nuclear Medicine and imaging
  • Condensed Matter Physics

Cite this

MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T. / Place, David A.; Faustino, Patrick J.; Berghmans, Kirsten K.; Van Zijl, Peter C; Chesnick, A. Scott; Cohen, Jack S.

In: Magnetic Resonance Imaging, Vol. 10, No. 6, 1992, p. 919-928.

Research output: Contribution to journalArticle

Place, David A. ; Faustino, Patrick J. ; Berghmans, Kirsten K. ; Van Zijl, Peter C ; Chesnick, A. Scott ; Cohen, Jack S. / MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T. In: Magnetic Resonance Imaging. 1992 ; Vol. 10, No. 6. pp. 919-928.
@article{ae2c9746fa3c4f158ccc4a876aecccec,
title = "MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T",
abstract = "Previously we reported that Mn(III)tetra(4-sulfonatophenyl) porphyrin, MnTPPS4, is a contrast agent which can effectively enhance tumor detection by MRI. By imaging 30 additional athymic nude mice bearing subcutaneous MCF-7 WT human breast carcinoma xenografts, we have extended dose-contrast relationships over a wide range of intraperitoneal (IP) doses ranging from 0.025 to 0.50 mmol/kg. The benefits of IP injection are higher possible doses on a volume basis and a reduction in toxicity versus IV administration. Full coronal cross-section images have been obtained on a 2-T spectrometer. Although individual tumor masses displayed different distribution patterns, reflective of their internal morphology, single doses of 0.10 mmol/kg or greater were necessary to produce a detectable effect. At a dose of 0.50 mmol/kg, marked enhancement was produced. Multiple small dosages administered over the course of several days before imaging did not produce increased enhancement. Preliminary results on the new porphyrin derivative, MnTPPS3, indicate that the ratio of the toxic dose to the effective dose may be adjustable to render this class of agents clinically useful.",
keywords = "Contrast agent, MnTPPS, Porphyrin, Tumor",
author = "Place, {David A.} and Faustino, {Patrick J.} and Berghmans, {Kirsten K.} and {Van Zijl}, {Peter C} and Chesnick, {A. Scott} and Cohen, {Jack S.}",
year = "1992",
doi = "10.1016/0730-725X(92)90446-7",
language = "English (US)",
volume = "10",
pages = "919--928",
journal = "Magnetic Resonance Imaging",
issn = "0730-725X",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T

AU - Place, David A.

AU - Faustino, Patrick J.

AU - Berghmans, Kirsten K.

AU - Van Zijl, Peter C

AU - Chesnick, A. Scott

AU - Cohen, Jack S.

PY - 1992

Y1 - 1992

N2 - Previously we reported that Mn(III)tetra(4-sulfonatophenyl) porphyrin, MnTPPS4, is a contrast agent which can effectively enhance tumor detection by MRI. By imaging 30 additional athymic nude mice bearing subcutaneous MCF-7 WT human breast carcinoma xenografts, we have extended dose-contrast relationships over a wide range of intraperitoneal (IP) doses ranging from 0.025 to 0.50 mmol/kg. The benefits of IP injection are higher possible doses on a volume basis and a reduction in toxicity versus IV administration. Full coronal cross-section images have been obtained on a 2-T spectrometer. Although individual tumor masses displayed different distribution patterns, reflective of their internal morphology, single doses of 0.10 mmol/kg or greater were necessary to produce a detectable effect. At a dose of 0.50 mmol/kg, marked enhancement was produced. Multiple small dosages administered over the course of several days before imaging did not produce increased enhancement. Preliminary results on the new porphyrin derivative, MnTPPS3, indicate that the ratio of the toxic dose to the effective dose may be adjustable to render this class of agents clinically useful.

AB - Previously we reported that Mn(III)tetra(4-sulfonatophenyl) porphyrin, MnTPPS4, is a contrast agent which can effectively enhance tumor detection by MRI. By imaging 30 additional athymic nude mice bearing subcutaneous MCF-7 WT human breast carcinoma xenografts, we have extended dose-contrast relationships over a wide range of intraperitoneal (IP) doses ranging from 0.025 to 0.50 mmol/kg. The benefits of IP injection are higher possible doses on a volume basis and a reduction in toxicity versus IV administration. Full coronal cross-section images have been obtained on a 2-T spectrometer. Although individual tumor masses displayed different distribution patterns, reflective of their internal morphology, single doses of 0.10 mmol/kg or greater were necessary to produce a detectable effect. At a dose of 0.50 mmol/kg, marked enhancement was produced. Multiple small dosages administered over the course of several days before imaging did not produce increased enhancement. Preliminary results on the new porphyrin derivative, MnTPPS3, indicate that the ratio of the toxic dose to the effective dose may be adjustable to render this class of agents clinically useful.

KW - Contrast agent

KW - MnTPPS

KW - Porphyrin

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0027058777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027058777&partnerID=8YFLogxK

U2 - 10.1016/0730-725X(92)90446-7

DO - 10.1016/0730-725X(92)90446-7

M3 - Article

C2 - 1461089

AN - SCOPUS:0027058777

VL - 10

SP - 919

EP - 928

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

SN - 0730-725X

IS - 6

ER -